Tarık Onur Tiryaki
Research Subjects
Tarık Onur Tiryaki has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Meliha Nalcaci
İstanbul Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul University, 34093 İstanbul, Türkiye
6 shared publications - Sevgi Kalayoğlu Beşışık
Department of Internal Medicine, Division of Hematology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
5 shared publications - Ipek Yonal-Hindilerden
Istanbul University Faculty of Medicine, Department of Adult Hematopoietic Stem Cell Transplantation Unit, Istanbul, Turkey
4 shared publications Meliha Nalçacı
Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, Istanbul, Turkey
3 shared publicationsAkif Selim Yavuz
Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Istanbul University, Istanbul, Turkey
2 shared publications- Ali Yılmaz Altay
İstanbul University, İstanbul Faculty of Medicine, Department of Pathology, İstanbul, Türkiye
2 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by MDPI AG in Preprints.org
Microbiota Changes During Chemotherapy in Hodgkin and Non-Hodgkin Lymphoma: A Comparative Assessment with Il-17 and Il-12 Levels
Objective: This study aimed to investigate changes in gut microbiota composition during chemotherapy in patients with Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and healthy controls, and to evaluate their potential impact on treatment outcomes. Additionally, changes in IL-12 and IL-17 levels during chemotherapy were assessed. Materials and Methods: Fifteen samples from patients with HL were collected after 2–3 cycles of therapy, whereas 15 samples from patients with NHL were collected after 3–4 cycles of therapy. Samples were also collected from healthy controls (n = 33). Microbial alpha diversity and microbiota composition were assessed using 16S rRNA gene sequencing and an operational taxonomic unit (OTU) table generated through R/RStudio. The expression levels of IL-12 and IL-17 were quantified by real-time quantitative PCR (RT-qPCR). Results: In HL patients, genera such as Agathobacter, Romboutsia, and Veillonella were predominantly identified in pre-treatment samples, whereas Dorea, Lactobacillus, and Weissella were enriched post-treatment. Actinobacteriota and Verrucomicrobiota were slightly more abundant before treatment. In NHL patients, Alistipes, Phascolarctobacterium, and Roseburia were characteristic of pre-treatment samples, while Lachnoclostridium, Parabacteroides, and UBA1819 were enriched post-treatment. Actinobacteriota levels increased modestly after chemotherapy. KEGG pathway analysis revealed distinct alterations in HL and NHL, and IL-12 levels differed significantly between NHL patients and healthy controls post-chemotherapy. Conclusions: Baseline gut microbiota profiling may help develop personalized strategies to mitigate chemotherapy-induced dysbiosis and enhance treatment efficacy. Microbiome modulation represents a promising adjunctive approach in lymphoma management.
- 26 October 2026
- Published by MDPI AG in Preprints.org
Open AccessMicrobiota Changes During Chemotherapy in Hodgkin and Non-Hodgkin Lymphoma: A Comparative Assessment with Il-17 and Il-12 Levels
Objective: This study aimed to investigate changes in gut microbiota composition during chemotherapy in patients with Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and healthy controls, and to evaluate their potential impact on treatment outcomes. Additionally, changes in IL-12 and IL-17 levels during chemotherapy were assessed. Materials and Methods: Fifteen samples from patients with HL were collected after 2–3 cycles of therapy, whereas 15 samples from patients with NHL were collected after 3–4 cycles of therapy. Samples were also collected from healthy controls (n = 33). Microbial alpha diversity and microbiota composition were assessed using 16S rRNA gene sequencing and an operational taxonomic unit (OTU) table generated through R/RStudio. The expression levels of IL-12 and IL-17 were quantified by real-time quantitative PCR (RT-qPCR). Results: In HL patients, genera such as Agathobacter, Romboutsia, and Veillonella were predominantly identified in pre-treatment samples, whereas Dorea, Lactobacillus, and Weissella were enriched post-treatment. Actinobacteriota and Verrucomicrobiota were slightly more abundant before treatment. In NHL patients, Alistipes, Phascolarctobacterium, and Roseburia were characteristic of pre-treatment samples, while Lachnoclostridium, Parabacteroides, and UBA1819 were enriched post-treatment. Actinobacteriota levels increased modestly after chemotherapy. KEGG pathway analysis revealed distinct alterations in HL and NHL, and IL-12 levels differed significantly between NHL patients and healthy controls post-chemotherapy. Conclusions: Baseline gut microbiota profiling may help develop personalized strategies to mitigate chemotherapy-induced dysbiosis and enhance treatment efficacy. Microbiome modulation represents a promising adjunctive approach in lymphoma management.
- 13 July 2026
- Published by Doc Design and Informatics Co. Ltd. in Turkish Journal of Immunology
The Impact of HLA Eplet Mismatching on GVHD, Relapse, and Survival Following Hematopoietic Stem Cell Transplantation: A Multidimensional Clinical and Statistical Evaluation
Objective: Graft-versus-host disease (GVHD) remains one of the leading causes of morbidity and mortality following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Even when conventional HLA matching is achieved, epitope-level discrepancies may still trigger alloimmune responses. Eplet mismatching represents a novel and more sensitive parameter for evaluating such immune incompatibilities and has gained increasing importance in predicting transplant outcomes. In this study, the associations between donor- and recipient-directed Class I and Class II eplet mismatches and the development of acute/chronic GVHD, relapse, and overall survival (OS) were investigated. Materials and Methods: A total of 56 allo-HSCT recipients followed at the Department of Hematology, Istanbul Faculty of Medicine, were included in this study. According to HLA matching, 18 patients received 5/10 matched, 7 received 6/10 matched, 1 received 7/10 matched, 2 received 8/10 matched, and 28 received 9/10 matched transplants. High-resolution HLA typing was performed using next-generation sequencing (NGS) for all patients. Donor–recipient eplet mismatches at HLA-A, -B, -C, -DRB1, and -DQB1 loci were calculated using the HLAMatchmaker algorithm. Clinical endpoints included GVHD, relapse, and overall survival. Statistical analyses were performed using multivariate Kruskal–Wallis and Dunn–Bonferroni post hoc tests, Cox proportional hazards regression, and logistic regression models. Results: Donor-directed Class II eplet mismatching was significantly higher in patients who developed chronic GVHD (p1, p<0.05). Kaplan–Meier survival analysis demonstrated that a high Class II eplet burden was significantly associated with reduced overall survival (p1, p<0.05). When relapse was added to the model, the risk of mortality increased markedly (HR≫1), while the effect of Class II eplet mismatching diminished, indicating that Class II mismatching affects mortality indirectly through relapse and/or chronic GVHD. In contrast, Class I eplet mismatching showed no significant effect on GVHD, relapse, or overall survival. Conclusion: Our findings demonstrate that Class II eplet mismatching adversely affects survival indirectly by increasing the risk of chronic GVHD and relapse. In contrast, the impact of Class I eplet mismatching appears to be limited. These results are consistent with previous reports indicating that HLA-DR/DQ eplet disparities enhance alloreactive T-cell activation and increase the risk of chronic GVHD and relapse. In conclusion, eplet-level matching provides a more sensitive and predictive approach for evaluating transplant outcomes compared with conventional antigen-based HLA matching. Incorporating eplet mismatch analysis into donor selection strategies may improve risk stratification and post-transplant prognosis. Keywords: Eplet analysis, HLA, GVHD, HSCT
- 13 July 2026
- Published by Doc Design and Informatics Co. Ltd. in Turkish Journal of Immunology
The Impact of HLA Eplet Mismatching on GVHD, Relapse, and Survival Following Hematopoietic Stem Cell Transplantation: A Multidimensional Clinical and Statistical Evaluation
Objective: Graft-versus-host disease (GVHD) remains one of the leading causes of morbidity and mortality following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Even when conventional HLA matching is achieved, epitope-level discrepancies may still trigger alloimmune responses. Eplet mismatching represents a novel and more sensitive parameter for evaluating such immune incompatibilities and has gained increasing importance in predicting transplant outcomes. In this study, the associations between donor- and recipient-directed Class I and Class II eplet mismatches and the development of acute/chronic GVHD, relapse, and overall survival (OS) were investigated. Materials and Methods: A total of 56 allo-HSCT recipients followed at the Department of Hematology, Istanbul Faculty of Medicine, were included in this study. According to HLA matching, 18 patients received 5/10 matched, 7 received 6/10 matched, 1 received 7/10 matched, 2 received 8/10 matched, and 28 received 9/10 matched transplants. High-resolution HLA typing was performed using next-generation sequencing (NGS) for all patients. Donor–recipient eplet mismatches at HLA-A, -B, -C, -DRB1, and -DQB1 loci were calculated using the HLAMatchmaker algorithm. Clinical endpoints included GVHD, relapse, and overall survival. Statistical analyses were performed using multivariate Kruskal–Wallis and Dunn–Bonferroni post hoc tests, Cox proportional hazards regression, and logistic regression models. Results: Donor-directed Class II eplet mismatching was significantly higher in patients who developed chronic GVHD (p1, p<0.05). Kaplan–Meier survival analysis demonstrated that a high Class II eplet burden was significantly associated with reduced overall survival (p1, p<0.05). When relapse was added to the model, the risk of mortality increased markedly (HR≫1), while the effect of Class II eplet mismatching diminished, indicating that Class II mismatching affects mortality indirectly through relapse and/or chronic GVHD. In contrast, Class I eplet mismatching showed no significant effect on GVHD, relapse, or overall survival. Conclusion: Our findings demonstrate that Class II eplet mismatching adversely affects survival indirectly by increasing the risk of chronic GVHD and relapse. In contrast, the impact of Class I eplet mismatching appears to be limited. These results are consistent with previous reports indicating that HLA-DR/DQ eplet disparities enhance alloreactive T-cell activation and increase the risk of chronic GVHD and relapse. In conclusion, eplet-level matching provides a more sensitive and predictive approach for evaluating transplant outcomes compared with conventional antigen-based HLA matching. Incorporating eplet mismatch analysis into donor selection strategies may improve risk stratification and post-transplant prognosis. Keywords: Eplet analysis, HLA, GVHD, HSCT
- Open Access
- 13 April 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (6) , 864-872
Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias
In this study, we aimed to compare the engraftment days, graft-versus-host disease (GVHD) development, relapse and overall survival rates in patients using myeloablative/reduced intensity conditioning regimens with posttransplant cyclophosphamide (PTCy) 25 mg/kg x2 with Anti-T lymphocyte Globulin (ATLG) (n = 29) and PTCy 50 mg/kg x2 doses (n = 41) in patients with acute leukemias. Matched related, matched unrelated, 1 mismatched unrelated, and haploidentical donors were selected for the patients. Platelet (median 11 vs 17 days) and neutrophil (median 14 vs 15 days) engraftment times were shorter in ATLG+ PTCy25 treated patients (both p < 0.05); veno-occlusive disease rates, graft failure and poor graft functions were similar between the two approaches (all p > 0.05); cumulative incidences of grade II-IV aGVHD at +100 days, grade III-IV aGVHD at +100 days, and grade II-IV cGVHD at 1-year were comparable between ATLG+PTCy25 and PTCy50 groups (all p > 0.05). Cumulative incidences of relapse and non-relapse mortality at 1-year were similar in two cohorts (both p > 0.05). PTCy50 was associated with a statistically significant benefit in terms of GVHD-free/relapse-free survival (GRFS) at 1-year (p = 0.03). Median GRFS was 115 (95% CI: 42–214) days and 248 (95% CI: 151-not reached) days, respectively [HR was 0.51 (0.28–0.95), p = 0.03; GRFS at 1-year was 20.7% vs 44.3%, respectively]. However, the groups were comparable in terms of PFS and OS. Median PFS was 332 days (95% CI: 182 days-not reached) for ATLG+PTCy25 group. It was not reached (95% CI: 210 days-not reached) for the patients who received PTCy50. Median OS was not reached in either ATLG+PTCy25 (95% CI: 191 days-not reached) or PTCy50 groups (Log rank = 0.42). Our study showed that lowering PTCy dose with ATLG seems to accelerate platelet and neutrophil engraftment rates; confers similar survival and relapse rates, similar acute and chronic GVHD frequency despite increased GRFS at 1-year.
- 13 April 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (6) , 864-872
Open AccessAnti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias
In this study, we aimed to compare the engraftment days, graft-versus-host disease (GVHD) development, relapse and overall survival rates in patients using myeloablative/reduced intensity conditioning regimens with posttransplant cyclophosphamide (PTCy) 25 mg/kg x2 with Anti-T lymphocyte Globulin (ATLG) (n = 29) and PTCy 50 mg/kg x2 doses (n = 41) in patients with acute leukemias. Matched related, matched unrelated, 1 mismatched unrelated, and haploidentical donors were selected for the patients. Platelet (median 11 vs 17 days) and neutrophil (median 14 vs 15 days) engraftment times were shorter in ATLG+ PTCy25 treated patients (both p < 0.05); veno-occlusive disease rates, graft failure and poor graft functions were similar between the two approaches (all p > 0.05); cumulative incidences of grade II-IV aGVHD at +100 days, grade III-IV aGVHD at +100 days, and grade II-IV cGVHD at 1-year were comparable between ATLG+PTCy25 and PTCy50 groups (all p > 0.05). Cumulative incidences of relapse and non-relapse mortality at 1-year were similar in two cohorts (both p > 0.05). PTCy50 was associated with a statistically significant benefit in terms of GVHD-free/relapse-free survival (GRFS) at 1-year (p = 0.03). Median GRFS was 115 (95% CI: 42–214) days and 248 (95% CI: 151-not reached) days, respectively [HR was 0.51 (0.28–0.95), p = 0.03; GRFS at 1-year was 20.7% vs 44.3%, respectively]. However, the groups were comparable in terms of PFS and OS. Median PFS was 332 days (95% CI: 182 days-not reached) for ATLG+PTCy25 group. It was not reached (95% CI: 210 days-not reached) for the patients who received PTCy50. Median OS was not reached in either ATLG+PTCy25 (95% CI: 191 days-not reached) or PTCy50 groups (Log rank = 0.42). Our study showed that lowering PTCy dose with ATLG seems to accelerate platelet and neutrophil engraftment rates; confers similar survival and relapse rates, similar acute and chronic GVHD frequency despite increased GRFS at 1-year.
- Open Access
- 11 September 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 6) , S415-S416
Analysis of cerebrospinal fluid chimerism after hematopoietic stem cell transplantation: Case report
- 11 September 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 6) , S415-S416
Open AccessAnalysis of cerebrospinal fluid chimerism after hematopoietic stem cell transplantation: Case report
- Open Access
- 3 November 2023
- Published by The European Research Journal in The European Research Journal
- Vol. 9 (6) , 1368-1379
Comparison of different plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilizers
Objectives: The main objective of the present study was to evaluate whether the use of plerixafor in combination with granulocyte colony-stimulating factor (G-CSF) or subsequent use of isolated G-CSF and then plerixafor following disease-specific chemotherapy, and whether it would allow for adequate peripheral stem cell collection in patients. Methods: The retrospective study evaluated 54 patients with previous mobilization failure who were administered plerixafor in 2 centers. In patients without any side effects, CD 34+ cell counts, the percentage of patients who were found eligible for autologous transplantation, the engraftment kinetics of the patients who underwent transplantation, and their overall survival results were compared between the two groups where G-CSF was used with plerixafor, or where plerixafor was used after isolated G-CSF following chemotherapy. Results: The median age of the patients was 49 years (range: 17-70), and 64.8% (n = 35) were males. It was identified that 31 (57.4%) patients underwent mobilization treatment with isolated G-CSF and plerixafor, and 23 (42.6%) patients underwent mobilization treatment with chemotherapy plus G-CSF and plerixafor. In all patients, mean hemoglobin level (11.3 ± 1.5 g/dL vs. 9.3 ± 1.3 g/dL; p < 0.001) and median platelet level (129.2 ×103/µL vs. 58.4 ×103/µL) were found to be higher, while febrile neutropenia rate (3.3% vs. 60.9%), the percentage of replacement patients (6.7% vs. 65.2%), and median days of G-CSF (6 vs. 9) were found to be lower on the day of plerixafor administration in the isolated G-CSF and plerixafor group compared to the chemotherapy and G-CSF and plerixafor group. Conclusions: In conclusion, our study demonstrated that administration of plerixafor is generally safe and well-tolerated. Regardless of the underlying disease, it offers an effective alternative for patients with previous failed mobilization attempts using conventional regimens, and allows stem cell collection with fewer apheresis sessions.
- 3 November 2023
- Published by The European Research Journal in The European Research Journal
- Vol. 9 (6) , 1368-1379
Open AccessComparison of different plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilizers
Objectives: The main objective of the present study was to evaluate whether the use of plerixafor in combination with granulocyte colony-stimulating factor (G-CSF) or subsequent use of isolated G-CSF and then plerixafor following disease-specific chemotherapy, and whether it would allow for adequate peripheral stem cell collection in patients. Methods: The retrospective study evaluated 54 patients with previous mobilization failure who were administered plerixafor in 2 centers. In patients without any side effects, CD 34+ cell counts, the percentage of patients who were found eligible for autologous transplantation, the engraftment kinetics of the patients who underwent transplantation, and their overall survival results were compared between the two groups where G-CSF was used with plerixafor, or where plerixafor was used after isolated G-CSF following chemotherapy. Results: The median age of the patients was 49 years (range: 17-70), and 64.8% (n = 35) were males. It was identified that 31 (57.4%) patients underwent mobilization treatment with isolated G-CSF and plerixafor, and 23 (42.6%) patients underwent mobilization treatment with chemotherapy plus G-CSF and plerixafor. In all patients, mean hemoglobin level (11.3 ± 1.5 g/dL vs. 9.3 ± 1.3 g/dL; p < 0.001) and median platelet level (129.2 ×103/µL vs. 58.4 ×103/µL) were found to be higher, while febrile neutropenia rate (3.3% vs. 60.9%), the percentage of replacement patients (6.7% vs. 65.2%), and median days of G-CSF (6 vs. 9) were found to be lower on the day of plerixafor administration in the isolated G-CSF and plerixafor group compared to the chemotherapy and G-CSF and plerixafor group. Conclusions: In conclusion, our study demonstrated that administration of plerixafor is generally safe and well-tolerated. Regardless of the underlying disease, it offers an effective alternative for patients with previous failed mobilization attempts using conventional regimens, and allows stem cell collection with fewer apheresis sessions.
- Open Access
- 24 January 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-11
Comprehensive mastocytosis data analysis from a single center
Mastocytosis is a very rare disorder and is divided into three prognostically distinct variants by World Health Organization: Cutaneous mastocytosis (CM), systemic mastocytosis (SM), and mast cell sarcoma or localized mast cell (MC) tumors. The wide range of complaints may cause patients to consult various clinics, with resulting mis- or underdiagnosis. Therefore, cooperation between different subspecialties is of paramount importance. In this article, we have compiled 104 adult mastocytosis cases diagnosed and followed in our Hematology and other clinics. 86 (82.7%) of 104 patients had systemic mastocytosis. Osteoporosis, disease-related complications, and secondary malignancies are important topics in this group. We know that indolent form has great survival. But smoldering or aggressive mastocytosis has a poor prognosis. CM and indolent SM have a significantly better prognosis compared to aggressive SM (p < 0.001). We found that the presence of more than 25% of mast cells in the bone marrow, the presence of concomitant marrow dysplasia, and the presence of disease-related complications affect survival (p < 0.001). In addition to the WHO classification, the IPSM scoring system is indicative of the prognosis in this rare disease.
- 24 January 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-11
Open AccessComprehensive mastocytosis data analysis from a single center
Mastocytosis is a very rare disorder and is divided into three prognostically distinct variants by World Health Organization: Cutaneous mastocytosis (CM), systemic mastocytosis (SM), and mast cell sarcoma or localized mast cell (MC) tumors. The wide range of complaints may cause patients to consult various clinics, with resulting mis- or underdiagnosis. Therefore, cooperation between different subspecialties is of paramount importance. In this article, we have compiled 104 adult mastocytosis cases diagnosed and followed in our Hematology and other clinics. 86 (82.7%) of 104 patients had systemic mastocytosis. Osteoporosis, disease-related complications, and secondary malignancies are important topics in this group. We know that indolent form has great survival. But smoldering or aggressive mastocytosis has a poor prognosis. CM and indolent SM have a significantly better prognosis compared to aggressive SM (p < 0.001). We found that the presence of more than 25% of mast cells in the bone marrow, the presence of concomitant marrow dysplasia, and the presence of disease-related complications affect survival (p < 0.001). In addition to the WHO classification, the IPSM scoring system is indicative of the prognosis in this rare disease.
- Open Access
- 1 December 2022
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 39 (4) , 254-261
Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
Objective: Redditux (R) (RED), as a biosimilar rituximab, was approved in Turkey for all indications of the original Mabthera (R) (MAB) in March 2018. The aim of our study was to evaluate the efficacy and safety of RED in de novo diffuse large B-cell lymphoma. Materials and Methods: Fifty-one patients received RED combined with the CHOP regimen. The median follow-up was 31 months. The historical control group included 219 patients treated with the MAB-CHOP regimen and the median follow-up time was 38 months. We compared the response rates and survival outcomes of these RED-CHOP and MAB-CHOP cohorts. Results: In the RED cohort, the overall response rate (ORR) at the end of the treatment protocol was 86%, with 37 (72.5%) cases of complete response (CR) and 7 (13.5%) cases of partial response (PR). In the historical MAB cohort, the ORR was 84%, with CR and PR rates of 82% and 2%, respectively. The 24-month progression-free survival (PFS) rates were 73.76% (95% confidence interval [CI]: 0.59-0.84) and 85.2% (95% CI: 0.79-0.90) for the RED and MAB cohorts, respectively (p=0.0106). The 24-month overall survival rates were 78.4% (95% CI: 0.64-0.87) and 81.4% (95% CI: 0.75-0.86) for the RED and MAB cohorts, respectively (p=0.7461). For patients with high revised International Prognostic Index scores, 24-month PFS was 45.5% (95% CI: 0.17-0.71) and 63% (95% CI: 0.37-0.80) for the RED and MAB cohorts, respectively (p=0.0711). In the RED cohort, central nervous system (CNS) relapse was significantly increased compared to the MAB cohort (10% vs. 1.83%, p=0.004). Among the RED cohort, bone involvement at the time of diagnosis was a risk factor for CNS relapse (p=0.028). Thirteen patients died in follow-up. There were no serious adverse events causing the cessation of the drugs. Conclusion: RED has an ORR similar to that of MAB. However, PFS rates were worse in the RED cohort. Additionally, CNS relapse ratio was a major concern for our RED cohort. Large prospective controlled studies and real-life data with longer follow-up are needed to document the non-inferiority of RED compared to MAB.
- 1 December 2022
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 39 (4) , 254-261
Open AccessBiosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
Objective: Redditux (R) (RED), as a biosimilar rituximab, was approved in Turkey for all indications of the original Mabthera (R) (MAB) in March 2018. The aim of our study was to evaluate the efficacy and safety of RED in de novo diffuse large B-cell lymphoma. Materials and Methods: Fifty-one patients received RED combined with the CHOP regimen. The median follow-up was 31 months. The historical control group included 219 patients treated with the MAB-CHOP regimen and the median follow-up time was 38 months. We compared the response rates and survival outcomes of these RED-CHOP and MAB-CHOP cohorts. Results: In the RED cohort, the overall response rate (ORR) at the end of the treatment protocol was 86%, with 37 (72.5%) cases of complete response (CR) and 7 (13.5%) cases of partial response (PR). In the historical MAB cohort, the ORR was 84%, with CR and PR rates of 82% and 2%, respectively. The 24-month progression-free survival (PFS) rates were 73.76% (95% confidence interval [CI]: 0.59-0.84) and 85.2% (95% CI: 0.79-0.90) for the RED and MAB cohorts, respectively (p=0.0106). The 24-month overall survival rates were 78.4% (95% CI: 0.64-0.87) and 81.4% (95% CI: 0.75-0.86) for the RED and MAB cohorts, respectively (p=0.7461). For patients with high revised International Prognostic Index scores, 24-month PFS was 45.5% (95% CI: 0.17-0.71) and 63% (95% CI: 0.37-0.80) for the RED and MAB cohorts, respectively (p=0.0711). In the RED cohort, central nervous system (CNS) relapse was significantly increased compared to the MAB cohort (10% vs. 1.83%, p=0.004). Among the RED cohort, bone involvement at the time of diagnosis was a risk factor for CNS relapse (p=0.028). Thirteen patients died in follow-up. There were no serious adverse events causing the cessation of the drugs. Conclusion: RED has an ORR similar to that of MAB. However, PFS rates were worse in the RED cohort. Additionally, CNS relapse ratio was a major concern for our RED cohort. Large prospective controlled studies and real-life data with longer follow-up are needed to document the non-inferiority of RED compared to MAB.
- Open Access
- 29 June 2022
- Published by Springer Nature in Research Square
Comprehensive Mastocytosis Data Analysis From A Single Center
Mastocytosis is a rare hematologic neoplasm that can present with involvement of different organs and variable complaints. The World Health Organization classification divides the disease into three prognostically distinct variants: Cutaneous mastocytosis (CM), systemic mastocytosis (SM) and mast cell sarcoma or localized mast cell (MC) tumors. SM is divided into subtypes according to the differences in organ involvement and signs of organ damage. The wide range of complaints may cause patients to consult various clinics, with resulting mis- or underdiagnosis. Therefore, the cooperation between different subspecialties is of paramount importance. In this article, we have compiled 104 adult mastocytosis cases diagnosed and followed in our Hematology clinic. The clinical and laboratory characteristics of the patients, therapies, complications and survival analysis is presented.
- 29 June 2022
- Published by Springer Nature in Research Square
Open AccessComprehensive Mastocytosis Data Analysis From A Single Center
Mastocytosis is a rare hematologic neoplasm that can present with involvement of different organs and variable complaints. The World Health Organization classification divides the disease into three prognostically distinct variants: Cutaneous mastocytosis (CM), systemic mastocytosis (SM) and mast cell sarcoma or localized mast cell (MC) tumors. SM is divided into subtypes according to the differences in organ involvement and signs of organ damage. The wide range of complaints may cause patients to consult various clinics, with resulting mis- or underdiagnosis. Therefore, the cooperation between different subspecialties is of paramount importance. In this article, we have compiled 104 adult mastocytosis cases diagnosed and followed in our Hematology clinic. The clinical and laboratory characteristics of the patients, therapies, complications and survival analysis is presented.
- 1 March 2022
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (3) , 169-173
The Real‐World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
- 1 March 2022
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (3) , 169-173
The Real‐World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL